MA29076B1 - Préparations pharmaceutiques comprenant un dérivé de camptothécine - Google Patents

Préparations pharmaceutiques comprenant un dérivé de camptothécine

Info

Publication number
MA29076B1
MA29076B1 MA29925A MA29925A MA29076B1 MA 29076 B1 MA29076 B1 MA 29076B1 MA 29925 A MA29925 A MA 29925A MA 29925 A MA29925 A MA 29925A MA 29076 B1 MA29076 B1 MA 29076B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparations
camptothecin derivative
camptothecin
derivative
preparations
Prior art date
Application number
MA29925A
Other languages
English (en)
Inventor
Isabel Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35691476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29076(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29076B1 publication Critical patent/MA29076B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA29925A 2004-11-19 2007-05-22 Préparations pharmaceutiques comprenant un dérivé de camptothécine MA29076B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62975704P 2004-11-19 2004-11-19

Publications (1)

Publication Number Publication Date
MA29076B1 true MA29076B1 (fr) 2007-12-03

Family

ID=35691476

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29925A MA29076B1 (fr) 2004-11-19 2007-05-22 Préparations pharmaceutiques comprenant un dérivé de camptothécine

Country Status (28)

Country Link
US (1) US8518961B2 (fr)
EP (1) EP1814520B1 (fr)
JP (1) JP4982378B2 (fr)
KR (1) KR101283840B1 (fr)
CN (1) CN101056619A (fr)
AR (1) AR052033A1 (fr)
AU (1) AU2005306018B2 (fr)
BR (1) BRPI0518448A2 (fr)
CA (1) CA2584343C (fr)
DK (1) DK1814520T3 (fr)
ES (1) ES2572133T3 (fr)
GT (1) GT200500310A (fr)
HR (1) HRP20160446T1 (fr)
HU (1) HUE027135T2 (fr)
IL (1) IL182703A (fr)
MA (1) MA29076B1 (fr)
MX (1) MX2007005897A (fr)
MY (1) MY148647A (fr)
NO (1) NO342592B1 (fr)
NZ (1) NZ554551A (fr)
PE (1) PE20061077A1 (fr)
PL (1) PL1814520T3 (fr)
RU (3) RU2007122470A (fr)
SI (1) SI1814520T1 (fr)
TN (1) TNSN07193A1 (fr)
TW (1) TWI368521B (fr)
WO (1) WO2006053755A1 (fr)
ZA (1) ZA200703148B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
BRPI0614757A2 (pt) * 2005-08-10 2011-04-12 Novartis Ag composição farmacêutica, micropartìcula e seu uso
CN101573111A (zh) * 2006-10-31 2009-11-04 惠氏公司 磷脂酶抑制剂的制剂
US20100070052A1 (en) * 2008-08-19 2010-03-18 Robb Fujioka System and method for providing applications and peripherals to a fixed price component-based computing platform
WO2012006081A1 (fr) 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Formulation orale d'inhibiteurs de kinases
WO2012012139A1 (fr) 2010-06-30 2012-01-26 Poniard Pharmaceuticals, Inc. Synthèse et utilisation d'inhibiteurs de la kinase
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
WO2024042523A1 (fr) * 2022-08-24 2024-02-29 Lyotropic Delivery Systems Ltd. Administration orale de composés actifs pour le traitement de maladies du stockage du glycogène

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH08504811A (ja) * 1992-12-24 1996-05-28 ヘマジェン／ピーエフシー フルオロカーボンのエマルジョン
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
CA2373994A1 (fr) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Excipient en emulsion pour medicaments faiblement solubles
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
AU2002362836B2 (en) 2001-10-15 2008-05-22 Crititech, Inc. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (fr) 2002-08-23 2004-03-03 Munich Biotech AG Compositions à base de carboxylate de camptothécine
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
KR20060110872A (ko) * 2003-10-29 2006-10-25 소너스파머슈티칼즈인코포레이티드 토코페롤 변성 치료제 약물 화합물
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
CN1893892B (zh) 2003-12-17 2012-03-28 比奥纽默里克药物公司 喜树碱的药物制剂和制备它们的方法
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
AU2005306018A1 (en) 2006-05-26
NZ554551A (en) 2010-01-29
RU2007122470A (ru) 2008-12-27
KR101283840B1 (ko) 2013-07-15
JP2008520606A (ja) 2008-06-19
TW200631606A (en) 2006-09-16
ZA200703148B (en) 2008-09-25
KR20070084357A (ko) 2007-08-24
BRPI0518448A2 (pt) 2008-11-18
RU2012120388A (ru) 2013-11-27
AU2005306018B2 (en) 2009-12-17
EP1814520B1 (fr) 2016-04-13
ES2572133T3 (es) 2016-05-30
MY148647A (en) 2013-05-15
CA2584343A1 (fr) 2006-05-26
NO342592B1 (no) 2018-06-18
PL1814520T3 (pl) 2016-08-31
IL182703A (en) 2015-11-30
CN101056619A (zh) 2007-10-17
AR052033A1 (es) 2007-02-28
TWI368521B (en) 2012-07-21
US20080125450A1 (en) 2008-05-29
JP4982378B2 (ja) 2012-07-25
PE20061077A1 (es) 2006-11-13
WO2006053755A1 (fr) 2006-05-26
RU2015131700A (ru) 2017-02-02
TNSN07193A1 (en) 2008-11-21
RU2620331C2 (ru) 2017-05-24
NO20072258L (no) 2007-08-10
CA2584343C (fr) 2013-09-24
SI1814520T1 (sl) 2016-06-30
US8518961B2 (en) 2013-08-27
HUE027135T2 (en) 2016-08-29
HRP20160446T1 (hr) 2016-05-20
IL182703A0 (en) 2007-09-20
GT200500310A (es) 2006-06-19
MX2007005897A (es) 2007-06-19
EP1814520A1 (fr) 2007-08-08
DK1814520T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
MA29076B1 (fr) Préparations pharmaceutiques comprenant un dérivé de camptothécine
MA28489B1 (fr) Preparations pharmaceutiques
IL177120A0 (en) Formulations for poorly soluble drugs
DE502004003234D1 (de) Gegen missbrauch gesicherte darreichungsform
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
DK1615615T3 (da) Manipulationssikre produkter til opioid tilførsel
FR2867064B1 (fr) Doseur de medicaments
DK1753764T3 (da) Pyrrolopyridin-derivater
GB0426301D0 (en) Pharmaceutical formulations
EP1718335A4 (fr) Conjugues de medicaments
DK2918286T3 (da) En farmaceutisk formulering
GB0416397D0 (en) Pharmaceutical formulations
GB0423800D0 (en) New pharmaceutical formulations
HK1105358A1 (en) Solid pharmaceutical formulation
ATE546141T1 (de) Pharmazeutisches injektionspräparat
DK1750765T3 (da) Farmaceutisk antimykobakteriesammensætning omfattende et antituberkulöst lægemiddel
IS8548A (is) Úðaþurrkaðar lyfjablöndur
GB0406048D0 (en) Drug formulations
EP1716865A4 (fr) Preparation pharmaceutique contenant de la paraoxonase
FI20040146A (fi) Farmaseuttiset valmisteet
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
DK2298766T3 (da) Farmaceutiske formuleringer omfattende et substitueret pyridinderivat
FI20040558A0 (fi) Farmaseuttinen valmiste